Big Pharma markets left on a ‘patent cliff’-h...

The US has launched new strikes on Iran, Ireland’s burning through its corporate tax bonanza, and the European Central Bank is trying to rein in fintech Revolut’s “self-guided missiles” in the region. Plus, the FT’s George Hammond breaks down whether public market investors belie ...  Show more

OpenAI filed to go public, Wall Street stocks rebounded on Monday, and top BP investors and former executives are concerned the UK oil major may lose momentum in its restructuring plan. Plus, Israel’s strikes on Lebanon are putting the US between a rock and a hard place.Mentioned ...  Show more

Four months ago, the FT’s Rob Armstrong and Elaine Moore placed their bets on two portfolios of three stocks each picked from the “Magnificent Seven” tech stocks that have been dominating markets this year. Today on the show, we check in on their portfolios, and try to think a ...

Mankind Pharma has announced it will buy biotech company BSV for a whopping Rs 13,630 crore. The deal brings together a master of mass market products and an intrinsic innovator in the high entry barrier spaces of the healthcare market. It’s an expensive buy and Mankind has gone ...  Show more

Patrick Bet-David sits down with whistleblower and author Dr. Peter C. Gøtzsche, who reveals why he calls Big Pharma “organized crime,” exposing the industry’s bribery, corruption, and dangerous practices hidden behind prescription drugs and corporate power.------🍋 ZEST IT FORWA ...  Show more

Today on Morning Brief, anchors Brad Smith and Seana Smith tackle the biggest market stories and speak to top Wall Street experts ahead of the opening bell. Our hosts analyze some of the top trending tickers: Spotify (SPOT), PepsiCo (PEP), Merck (MRK) Takeaways: China retaliates ...  Show more